Ensysce BiosciencesENSCW 23 Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus rates ENSCW with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 151 Biotechnology companies, Ensysce Biosciences ranks worse than 662250.99% on this metric.
As of today (2026-06-25), the Trailing Annual Dividend Yield of Ensysce Biosciences is 0.00%.
The historical rank and industry rank for Ensysce Biosciences's Dividend Yield % or its related term are showing as below:
ENSCW's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.5 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Ensysce Biosciences Dividend Yield % Related Terms
Ensysce Biosciences Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Ensysce Biosciences's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENSCW vs PPCB, ACUT, LSBCF: Dividend Yield % Comparison
For the Biotechnology subindustry, Ensysce Biosciences's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ensysce Biosciences Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ensysce Biosciences's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Ensysce Biosciences's Dividend Yield % falls into.
Ensysce Biosciences (ENSCW) has a Dividend Yield % of 0.00% as of Jun. 25, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Ensysce Biosciences and its competitors. According to the industry distribution chart, Ensysce Biosciences ranks #999999 out of 151 companies in the Biotechnology industry.
Is Ensysce Biosciences' Dividend Yield % too high?
Ensysce Biosciences' current Dividend Yield % is 0.00%. Based on the distribution chart, Ensysce Biosciences ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ensysce Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Ensysce Biosciences' Dividend Yield % compare to PPCB and ACUT?
According to the Biotechnology industry distribution chart, Ensysce Biosciences ranks #999999 out of 151 companies for Dividend Yield %. This places Ensysce Biosciences in the lower half of its industry. The industry median Dividend Yield % is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.50, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Ensysce Biosciences and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ensysce Biosciences's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ensysce Biosciences stock overvalued right now?
Ensysce Biosciences (ENSCW) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Ensysce Biosciences' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Ensysce Biosciences (ENSCW), the current Dividend Yield % is 0.00% as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score
Get the complete analysis for ENSCW
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENSCW has been successfully added to your 
